Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (6): 1229-1233. doi: 10.19723/j.issn.1671-167X.2022.06.029

Previous Articles     Next Articles

红霞 李1,雅馨 周1,亚飞 王2,鹏宇 王2,振彪 吴2,*()   

  • Received:2022-08-27 Online:2022-12-18 Published:2022-12-19
  • Contact: 振彪 吴 E-mail:wuzhenbiaoxjimmu@163.com
  • Supported by:
    National Key Research Development Program of China(201KTCL03_03)

RICH HTML

   

PDF (PC)

CLC Number: 

  • R593.2

Figure 1

Different changes of labial salivary glands in pSS patients A, normal pathology; B, lymphocyte infiltration (arrow) but no focus score (FS=0); C, non-specific chronic sialadenitis having lymphocyte infiltration (arrow); D, lymphocytic focuses (FS=6.3, arrow). FS, focus score; pSS, primary Sjögren's syndrome."

Table 1

Comparison of clinical parameters between positive-pSS and negative-pSS patients"

Variables Positive-pSS (n=104) Negative-pSS (n=113) Statistics P
Age/years, $\bar x \pm s$ 48.5±14.9 49.6±14.2 0.440 0.508
Gender (Males/Females), n 5/99 7/106 0.199 0.655
Duration/months, M(P25, P75) 12 (6, 45) 14 (6, 36) 0.802 0.423
Dry mouth 83 (79.8) 83 (73.4) 1.217 0.270
Dry eyes 62 (59.6) 59 (52.2) 1.203 0.273
Parotid swelling 11 (10.6) 15 (13.3) 0.374 0.541
Rampant caries 22 (21.2) 13 (11.5) 3.728 0.054
Arthralgia/Anthritis 16 (15.4) 28 (24.8) 2.957 0.086
Rash 20 (19.2) 22 (19.5) 0.002 0.965
Fever 5 (4.8) 8 (7.1) 0.496 0.481
Hematological involvement 34 (32.7) 34 (30.1) 0.171 0.680
  Leukocytopenia 29 (27.9) 22 (19.5) 2.133 0.144
  Thrombocytopenia 15 (14.4) 15 (13.3) 0.060 0.807
Interstitial pneumonia 10 (9.6) 10 (8.9) 0.038 0.846
Kidney involvement 7 (6.7) 5 (4.4) 0.551 0.458
Nerve involvement 5 (4.8) 9 (8.0) 0.894 0.344
WUSF rate≤0.1 mL/min 46/69 (66.7) 63/80 (78.8) 2.754 0.097
Schirmer test ≤ 5 mm/5 min 43/69 (62.3) 41/77 (53.2) 1.226 0.268
ESSDAI, $\bar x \pm s$ 6.7±5.4 5.7±4.4 3.486 0.063
  ESSDAI＜5 44 (42.3) 51 (45.1) 0.176 0.675
  5≤ESSDAI＜10 31 (29.8) 42 (37.2) 1.314 0.252
  ESSDAI≥10 29 (27.9) 20 (17.7) 3.214 0.073

Table 2

Comparison of immune indicators between positive-pSS and negative-pSS patients [n (%)]"

Variables Positive-pSS (n=104) Negative-pSS (n=113) Statistics P
ANA seropositive 101 (97.1) 111 (98.2) 0.009 0.925
  ANA titer = 1 ∶100 6 (5.8) 14 (12.4) 2.837 0.092
  ANA titer = 1 ∶320 9 (8.7) 20 (17.7) 3.723 0.054
  ANA titer = 1 ∶1 000 19 (18.3) 26 (23.0) 0.740 0.390
  ANA titer ≥ 1 ∶3 200 67 (64.4) 51 (45.1) 8.123 0.004
Anti-SSA 86 (82.7) 98 (86.7) 0.683 0.408
Anti-Ro-52 87 (83.7) 90 (79.6) 0.579 0.447
Anti-SSB 48 (46.2) 34 (30.1) 5.946 0.015
AMA-M2 8 (7.7) 15 (13.3) 1.781 0.182
Anti-CENP-B 8 (7.7) 10 (8.9) 0.095 0.757
Anti-RNP/Sm 11 (10.6) 12 (10.6) 0.000 0.992
Anti-dsDNA 0 1 (0.9)
Anti-CCP 1/40 (2.5) 2/43 (4.7) >0.999
IgG>1 600 mg/dL 71/96 (74.0) 60/99 (60.6) 3.941 0.047
IgA>450 mg/dL 18/96 (18.8) 13/99 (13.1) 1.151 0.283
IgM>270 mg/dL 9/96 (9.4) 7/99 (7.1) 0.344 0.558
C3 < 80 mg/dL 43/96 (44.8) 37/97 (38.1) 0.878 0.349
C4 < 16 mg/dL 36/96 (37.5) 33/97 (34.0) 0.254 0.614
RF seropositive 70/96 (72.9) 56/97 (57.7) 4.909 0.027
ESR>20 mm/h 48/83 (57.8) 31/82 (37.8) 6.629 0.010
CRP>0.8 mg/dL 9/94 (9.6) 5/97 (5.2) 1.373 0.241

Table 3

Analysis of variables associated with positive pathology in pSS patients"

Variables OR (95%CI) P value
Rampant caries 1.608 (0.723-3.576) 0.245
ANA titer ≥ 1 ∶3 200 1.592 (0.838-3.025) 0.155
Anti-SSB positive 1.190 (0.616-2.299) 0.604
ESR>20 mm/h 2.239 (0.657-2.337) 0.508
IgG>1 600 mg/dL 1.635 (0.813-3.290) 0.168
RF seropositive 0.875 (0.448-1.710) 0.696
ESSDAI
  ESSDAI < 5 Reference
  5≤ESSDAI < 10 0.711 (0.357-1.419) 0.334
  ESSDAI≥10 1.554 (0.723-3.340) 0.259
1 张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2020, 59 (4): 269- 270.
doi: 10.3760/cma.j.cn112138-20200113-00021
2 Mariette X , Criswell LA . Primary Sjögren' s syndrome[J]. N Engl J Med, 2018, 378 (10): 931- 939.
doi: 10.1056/NEJMcp1702514
3 Shiboski CH , Shiboski SC , Seror R , et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren' s syndrome: A consensus and data-driven methodology involving three international patient cohorts[J]. Ann Rheum Dis, 2017, 76 (1): 9- 16.
doi: 10.1136/annrheumdis-2016-210571
4 Seror R , Ravaud P , Bowman SJ , et al. EULAR Sjögren' s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2010, 69 (6): 1103- 1109.
doi: 10.1136/ard.2009.110619
5 Vitali C , Bombardieri S , Jonsson R , et al. Classification criteria for Sjögren' s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61 (6): 554- 558.
doi: 10.1136/ard.61.6.554
6 Guellec D , Cornec D , Jousse-Joulin S , et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren' s syndrome: A systematic review[J]. Autoimmun Rev, 2013, 12 (3): 416- 420.
doi: 10.1016/j.autrev.2012.08.001
7 Fisher BA , Jonsson R , Daniels T , et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2017, 76 (7): 1161- 1168.
doi: 10.1136/annrheumdis-2016-210448
8 Retamozo S , Acar-Denizli N , Rasmussen A , et al. Systemic manifestations of primary Sjögren' s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients[J]. Clin Exp Rheumatol, 2019, 37 (3/Suppl 118): 97- 106.
9 Luppi F , Sebastiani M , Silva M , et al. Interstitial lung disease in Sjögren' s syndrome: A clinical review[J]. Clin Exp Rheumatol, 2020, 38 (4/Suppl 126): 291- 300.
10 Lin W , Xin Z , Ning X , et al. Clinical features and risk factors of Raynaud' s phenomenon in primary Sjögren' s syndrome[J]. Clin Rheumatol, 2021, 40 (10): 4081- 4087.
doi: 10.1007/s10067-021-05749-w
11 Sharma R , Chaudhari KS , Kurien BT , et al. Sjögren syndrome without focal lymphocytic infiltration of the salivary glands[J]. J Rheumatol, 2020, 47 (3): 394- 399.
doi: 10.3899/jrheum.181443
12 Park Y , Lee J , Koh JH , et al. Positive histopathologic assessment in salivary glands shows little impact on clinical features of established primary Sjögren' s syndrome in a Korean population[J]. Clin Exp Rheumatol, 2020, 38 (4/ Suppl 126):): 158- 165.
13 Risselada AP , Kruize AA , Goldschmeding R , et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2014, 73 (8): 1537- 1540.
doi: 10.1136/annrheumdis-2013-204634
14 Kakugawa T , Sakamoto N , Ishimoto H , et al. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren' s syndrome[J]. Respir Med, 2018, 137, 95- 102.
doi: 10.1016/j.rmed.2018.02.023
15 Wu S , Tang X , Wu L , et al. Anti-Ro52 antibodies in clinical practice: A single-centre experience[J]. Int J Clin Pract, 2021, 75 (3): e13679.
[1] Jiayi TIAN, Yixue GUO, Xia ZHANG, Xiaolin SUN, Jing HE. Flow cytometry analysis of normal range of natural killer cells and their subsets in peripheral blood of healthy Chinese adults [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 839-844.
[2] Yushu YANG, Xuan QI, Meng DING, Wei WANG, Huifang GUO, Lixia GAO. Diagnostic values of anti-salivary gland protein-1 antibody combined with anti-parotid secretory protein antibody for Sjögren's syndrome [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 845-852.
[3] Hua ZHONG, Yuan LI, Liling XU, Mingxin BAI, Yin SU. Application of 18F-FDG PET/CT in rheumatic diseases [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 853-859.
[4] Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867.
[5] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[6] Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734.
[7] 佳佳 乔,聪 田,晓波 黄,军 刘. [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 745-749.
[8] Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[9] Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278.
[10] Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[11] Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.
[12] Yi-jun HAN,Chang-hong LI,Xiu-ying CHEN,Jin-xia ZHAO. Comparison of clinical and immunological characteristics between primary Sjögren's syndrome patients with positive and negative anti-SSB antibody [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1000-1006.
[13] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[14] Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[15] Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd